Multigene Panel Testing Results in Patients With Multiple Breast Cancer Primaries - PubMed

Multigene Panel Testing Results in Patients With Multiple Breast Cancer Primaries - PubMed

Multigene Panel Testing Results in Patients With Multiple Breast Cancer Primaries

Jessica Corredor 1, Ashley H Woodson 1, Angelica Gutierrez Barrera 2, Banu Arun 1 2

Affiliations 

• PMID: 31999039
 
• DOI: 10.1111/tbj.13762

Abstract

Currently, the NCCN guidelines recommend testing of BRCA1 and BRCA2 for females with multiple breast primaries, if her first diagnosis was ≤50 years old. With the increase in uptake of multigene panels, testing for genes outside of BRCA1 and BRCA2 has become more prevalent. This study looked at a single institution's cohort of women with multiple primary breast cancers that underwent panel testing to determine the rates of pathogenic mutations in non-BRCA genes. The genetic testing results for each individual were reviewed, along with patient characteristics. Descriptive analysis and two-tailed Z tests were used to analyze the data. Out of 85 eligible women, 33 (38.8%) tested positive for a pathogenic mutation in a cancer predisposition gene: 9 BRCA1, 5 BRCA2, 5 ATM, 1 BARD1, 4 CHEK2, 1 MSH2, 1 MSH6, 2 PALB2, 1 PMS2, 1 PTEN and 3 TP53. Overall, 17.6% tested positive for a non-BRCA breast cancer predisposition gene. There was no difference in the age of first or second breast cancer diagnosis in comparison with genetic testing outcomes. This study found a high positive rate for all individuals with multiple breast cancers, regardless of age, for both BRCA1 and BRCA2 and non-BRCA genes. Future studies should investigate whether individuals with multiple breast cancer primaries that do not meet BRCA1 and BRCA2 testing criteria should undergo genetic testing, regardless of the age of diagnosis.

Keywords: breast cancer predisposition genes; genetics; multiple breast primaries; panel testing.

© 2020 Wiley Periodicals, Inc.

Similar articles

• Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds

  ZA Catts et al. Ann Surg Oncol 23 (5), 1729-35. May 2016. PMID 26727920.

  This study demonstrates that a statewide high-risk family cancer registry is an important instrument in studying the risk of PC in families. Our analysis revealed 14 muta …
• High Frequency of Pathogenic Non-Founder Germline Mutations in BRCA1 and BRCA2 in Families With Breast and Ovarian Cancer in a Founder Population

  J Maksimenko et al. Hered Cancer Clin Pract 16, 12. 2018. PMID 29928469.

  A relatively high incidence of pathogenic non-founder BRCA1/2 mutations was observed in a founder population. The Manchester scoring system predicted the pr …
• Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer

  FJ Couch et al. JAMA Oncol 3 (9), 1190-1196. 2017. PMID 28418444.

  This study establishes several panel genes as high- and moderate-risk breast cancer genes and provides estimates of breast cancer risk associated with pathogenic variants …
• Genetic Tests for Breast and Ovarian Cancer [Internet]

  LK Juvet et al. Feb 2008. PMID 29319983. - Review

  Background Breast cancer is the most commonly diagnosed cancer in women. In 2005, there were about 3000 incident cases of breast cancer in Norway. Ovarian canc …
• Genetic Risk Assessment and Prevention: The Role of Genetic Testing Panels in Breast Cancer

  J Lerner-Ellis et al. Expert Rev Anticancer Ther 15 (11), 1315-26. 2015. PMID 26523341. - Review

  Multigene panel tests are being increasingly used for the genetic assessment of women with an apparent predisposition to breast cancer. Here, we review all studies report …

 See all similar articles

References

REFERENCES

1. 1. Kollias J, Ellis I, Elston C, Blamey R. Prognostic significance of synchronous and metachronous bilateral breast cancer. World J Surg. 2001;25(9):1117-1124.
2. 1. Bernstein JL, Lapinski RH, Thakore SS, Doucette JT, Thompson WD. The descriptive epidemiology of second primary breast cancer. Epidemiology. 2003;14(5):552-558.
3. 1. Kurian A, McClure L, Esther J, Horn-Ross P, Ford J, Clarke C. Second primary breast cancer occurrence according to hormone receptor status. JNCI. 2009;101(15):1058-1065.
4. 1. Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int. 2013;2013:1-11.
5. 1. Molina-Montes E, Perez-Nevot B, Pollan M, Sánchez-Cantalejo E, Espín J, Sánchez MJ. Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: a systematic review and meta-analysis. Breast. 2014;23:721-742.